Our top pick for
Novan, Inc is a biotechnology business based in the US. Novan shares (NOVN) are listed on the NASDAQ and all prices are listed in US Dollars. Novan employs 24 staff and has a trailing 12-month revenue of around USD$5.2 million.
Since the stock market crash in March caused by coronavirus, Novan's share price has had significant negative movement.
Its last market close was USD$0.491, which is 10.91% down on its pre-crash value of USD$0.5511 and 128.37% up on the lowest point reached during the March crash when the shares fell as low as USD$0.215.
If you had bought USD$1,000 worth of Novan shares at the start of February 2020, those shares would have been worth USD$1,246.74 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$984.96.
|Latest market close||USD$0.491|
|52-week range||USD$0.235 - USD$3.72|
|50-day moving average||USD$0.494|
|200-day moving average||USD$0.516|
|Wall St. target price||USD$2.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.959|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||0.491|
|1 month (2020-10-26)||-4.27%|
|3 months (2020-08-24)||9.09%|
|6 months (2020-05-22)||21.69%|
|1 year (2019-11-22)||-75.20%|
|2 years (2018-11-23)||-74.29%|
|3 years (2017-11-24)||-90.87%|
|5 years (2015-11-22)||N/A|
|Revenue TTM||USD$5.2 million|
|Gross profit TTM||USD$-5,020,000|
|Return on assets TTM||-36.78%|
|Return on equity TTM||0%|
|Market capitalisation||USD$66 million|
TTM: trailing 12 months
There are currently 5.5 million Novan shares held short by investors – that's known as Novan's "short interest". This figure is 9.7% up from 5.0 million last month.
There are a few different ways that this level of interest in shorting Novan shares can be evaluated.
Novan's "short interest ratio" (SIR) is the quantity of Novan shares currently shorted divided by the average quantity of Novan shares traded daily (recently around 9.2 million). Novan's SIR currently stands at 0.6. In other words for every 100,000 Novan shares traded daily on the market, roughly 600 shares are currently held short.
However Novan's short interest can also be evaluated against the total number of Novan shares, or, against the total number of tradable Novan shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novan's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Novan shares in existence, roughly 40 shares are currently held short) or 0.0393% of the tradable shares (for every 100,000 tradable Novan shares, roughly 39 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novan.
Find out more about how you can short Novan stock.
We're not expecting Novan to pay a dividend over the next 12 months.
Over the last 12 months, Novan's shares have ranged in value from as little as $0.235 up to $3.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novan's is -0.2626. This would suggest that Novan's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Novan has bucked the trend.
Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.